ArticleCancer management and research2018
Clinicopathological and survival analysis of uterine papillary serous carcinoma: a single institutional review of 106 cases.
Article in Cancer management and research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Primary cytoreductive surgery for advanced stage endometrial cancer: a systematic review and meta-analysis.American journal of obstetrics and gynecology · 2021Pooled it
- Article
- Prognostic characteristics, recurrence patterns and survival outcomes of uterine papillary serous carcinoma: a single-centre retrospective cohort study.Translational cancer research · 2026Article
- Diagnostic accuracy and prognostic factors of uterine serous carcinoma in Japanese women: a multi-center study.Journal of gynecologic oncology · 2025Article
- Aggressive Serous Carcinomas of the Female Reproductive Tract: Cancer-Prone Cell States and Genetic Drivers.Cancers · 2025Review
- Multiparametric MRI-based radiomics and deep learning for differentiating uterine serous carcinoma from endometrioid carcinoma: a multicenter retrospective study.Frontiers in oncology · 2025Article
- The clinico pathological features and survival in serous endometrial cancers.Gynecologic oncology reports · 2023Article
- Article
- Impact of the glutathione synthesis pathway on sulfasalazine-treated endometrial cancer.Oncotarget · 2022Article
- Comprehensive Study of Human FBXW7 Deleterious nsSNP's Functional Inference and Susceptibility to Gynaecological Cancer.Applied biochemistry and biotechnology · 2022Article
- Uterine serous carcinoma.Gynecologic oncology · 2021Review
- A 4-gene signature predicts prognosis of uterine serous carcinoma.BMC cancer · 2021Article
- PD-L1 Expression in Endometrial Serous Carcinoma and Its Prognostic Significance.Cancer management and research · 2021Article
- Proteomic profiling of FBXW7-mutant serous endometrial cancer cells reveals upregulation of PADI2, a potential therapeutic target.Cancer medicine · 2020Article
- A novel model to predict cancer-specific survival in patients with early-stage uterine papillary serous carcinoma (UPSC).Cancer medicine · 2020Article
- The role of omentectomy in the surgical treatment of uterine serous carcinoma.European journal of obstetrics & gynecology and reproductive biology: X · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe objectives of this study were to analyze clinicopathological features and to investigate the prognostic determinants in patients with uterine papillary serous carcinoma (UPSC). MATERIALS AND
methodsA cohort of 106 UPSC patients diagnosed and treated at Peking Union Medical College Hospital between 2000 and 2016 were retrospectively reviewed. The Kaplan-Meier method and Cox regression analysis were used for survival analysis. Differences between categorical data were calculated by using the chi-squared test.
resultsThe median follow-up was 29.0 months (range =2-170 months), with an overall recurrence rate of 35.8%. The coincidence rate between preoperative endometrial sampling and postoperative definitive pathology of hysteroscopy group was significantly higher than that of the dilation and curettage group (88.5% vs 65.0%,
conclusionIn patients with stage I UPSC, complete staging was associated with better OS, and therefore, it should be performed in all patients. Tumor stage and optimal cytoreduction are the most significant prognostic factors. Recurrence can be improved in stage I patients treated with adjuvant therapy and in patients with advanced-stage disease treated with combined therapy. TC regimen may be the preferred regimen for chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.